ACLX vs. QGEN, RGEN, PCVX, RVMD, EXEL, HALO, CRSP, KRYS, IBRX, and IMVT
Should you be buying Arcellx stock or one of its competitors? The main competitors of Arcellx include Qiagen (QGEN), Repligen (RGEN), Vaxcyte (PCVX), Revolution Medicines (RVMD), Exelixis (EXEL), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Krystal Biotech (KRYS), ImmunityBio (IBRX), and Immunovant (IMVT). These companies are all part of the "biological products, except diagnostic" industry.
Arcellx (NASDAQ:ACLX) and Qiagen (NYSE:QGEN) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, community ranking, earnings, analyst recommendations and valuation.
Qiagen has higher revenue and earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.
Arcellx presently has a consensus price target of $78.73, suggesting a potential upside of 50.70%. Qiagen has a consensus price target of $50.95, suggesting a potential upside of 19.48%. Given Arcellx's stronger consensus rating and higher probable upside, equities analysts clearly believe Arcellx is more favorable than Qiagen.
In the previous week, Arcellx had 3 more articles in the media than Qiagen. MarketBeat recorded 9 mentions for Arcellx and 6 mentions for Qiagen. Arcellx's average media sentiment score of 0.98 beat Qiagen's score of 0.68 indicating that Arcellx is being referred to more favorably in the media.
Qiagen has a net margin of 17.38% compared to Arcellx's net margin of -38.39%. Qiagen's return on equity of 12.59% beat Arcellx's return on equity.
96.0% of Arcellx shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 6.2% of Arcellx shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Qiagen received 199 more outperform votes than Arcellx when rated by MarketBeat users. However, 76.67% of users gave Arcellx an outperform vote while only 60.79% of users gave Qiagen an outperform vote.
Arcellx has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500.
Summary
Qiagen beats Arcellx on 10 of the 19 factors compared between the two stocks.
Get Arcellx News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
